Navigation Links
EpiCept Reports Regulatory Progress on Ceplene(TM)
Date:9/17/2007

se-free survival of AML patients by more than 50%. Importantly, this significant therapeutic benefit was achieved with a remarkably well-tolerated, self-administered immunotherapy."

EpiCept's MAA submission for Ceplene is being assessed under the EU centralized procedure, and if approved, will provide a marketing authorization valid in all EU member states, along with Iceland, Liechtenstein and Norway. The European Commission has previously granted orphan drug status to Ceplene for use in the treatment of AML. If the application for Ceplene continues to follow usual EU regulatory timelines, the next milestone on Ceplene's path to approval is expected to be the CHMP Day 180 list of outstanding issues, which EpiCept expects will be received in the fourth quarter of 2007. EpiCept expects this to be followed by a recommendation regarding approvability from the CHMP and a final decision by the European Commission during the first half of 2008.

About Ceplene

Ceplene is EpiCept's registration-stage compound for the treatment of AML. Ceplene is designed to protect lymphocytes responsible for immune-mediated destruction of residual leukemic cells. Laboratory research has demonstrated that Ceplene reduces formation of oxygen radicals from phagocytes, inhibiting NADPH oxidase and protecting IL-2-activated NK-cells and T-cells.

About Acute Myeloid Leukemia (AML)

AML is the most common form of acute leukemia in adults. There are approximately 47,000 AML patients in the EU, with 14,000 new cases occurring each year. For the majority of AML patients, the prospects for long-term survival are disappointing. Once diagnosed with AML, patients are treated with toxic chemotherapies. Although approximately 75% of patients achieve a complete remission, the leukemia frequently recurs (a "relapse"), usually within 1-2 years. Despite follow-up treatment that may include very toxic chemotherapy or bone marrow transplantation, only 10% to 20% of patients survive l
'/>"/>

SOURCE EpiCept Corporation
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. EpiCept Corporation to Present New NP-1 Data at American Pain Society Meeting
2. Mode of Action of EpiCept-Licensed Cancer Compound Profiled at AACR
3. Corgenix Reports New Clinical Data Correlating AtherOx Technology With Vascular Disease
4. Cobalis Reports Phase III Trial Results for PreHistin in Seasonal Allergic Rhinitis
5. Cosmo Pharmaceuticals Reports Positive Preliminary Phase II/III Data with Rifamycin MMX in Infectious Diarrhea
6. Cytos Biotechnology Reports Results from Phase IIa Study with CYT003-QbG10 in Patients Suffering from Atopic Dermatitis
7. Cytokinetics Reports Additional Clinical Trials Data for Ispinesib
8. The European Myeloma Platform Reports New Survival data for Revlimid Presented at the International Myeloma Workshop in Greece
9. Cytochroma Reports Positive Phase I Clinical Data for CTA018 Injection
10. Speedel Reports Successful SPP635 Phase IIa Trial in Hypertension
11. Columbia Laboratories Reports Positive Results from Multi-dose Pharmacokinetic Study of Vaginally-administered Lidocaine
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/24/2014)... Boston Children,s Hospital,s Global Pediatric Summit + ... an "Innovation Tank" – a forum designed to give ... business or product solution to a panel of acclaimed ... to accelerate the innovation and bring it to market. ... October 31, will be moderated by Daymond John ...
(Date:7/24/2014)... , July 24, 2014  To help ... cardiovascular market that could impact patient care and ... 2014 CV Watch , "Innovations in Cardiovascular Devices."  ... hospitals with guidance and details on promising new ... needs and understand how these options impact the ...
(Date:7/24/2014)... part of its ongoing effort to help women pharmacists become ... Boot Camp on July 26 as part of the company,s ... The Boot Camp is designed to ... their own pharmacies.  Now in its third year, the Cardinal ... pharmacists who dream of owning a pharmacy.   ...
Breaking Medicine Technology:Taking on Tomorrow to Feature "Innovation Tank" Pitch Opportunity for Aspiring Pediatric Health Care Entrepreneurs 2Taking on Tomorrow to Feature "Innovation Tank" Pitch Opportunity for Aspiring Pediatric Health Care Entrepreneurs 3New Novation CV Watch Shows Recent Technology Innovations Could Drive Cardiovascular Product Costs Up by as Much as 35 Percent 2New Novation CV Watch Shows Recent Technology Innovations Could Drive Cardiovascular Product Costs Up by as Much as 35 Percent 3'Women in Pharmacy' Program Seeks to Expand Pharmacy Ownership 2'Women in Pharmacy' Program Seeks to Expand Pharmacy Ownership 3'Women in Pharmacy' Program Seeks to Expand Pharmacy Ownership 4
... Association of Clinical Research Organizations (ACRO), which represents the ... and the public in the U.S. and worldwide, issued ... Implications of the Globalization of Clinical Research" published in ... England Journal of Medicine : The article by ...
... Journal of Medicine employs Quest Diagnostics, blood-based leukemia testingMADISON, ... specimens may detect abnormal white blood cells in patients ... develops, according to research published in the current issue ... Medicine . The finding may lead to a better ...
Cached Medicine Technology:ACRO Comments on NEJM Article on Globalization of Clinical Research 2ACRO Comments on NEJM Article on Globalization of Clinical Research 3Blood Testing Identifies Abnormal Cells Up to Six Years Prior to Leukemia Diagnosis 2Blood Testing Identifies Abnormal Cells Up to Six Years Prior to Leukemia Diagnosis 3Blood Testing Identifies Abnormal Cells Up to Six Years Prior to Leukemia Diagnosis 4
(Date:7/24/2014)... A new study led by the Translational Genomics Research ... viruses and the immune system during HIV infection. , ... to infect others based on their blood viral ... in their semen despite having low levels in their ... the virus can be found in different parts of ...
(Date:7/24/2014)... London, UK (PRWEB) July 24, 2014 Memantine ... and was first marketed in Germany under the brand name ... and other nations as Ebixa and in the USA to ... of USD 420 million in 2013. In the US, Forest ... , Patent protection expiry in Canada, Australia and the European ...
(Date:7/24/2014)... 24, 2014 Members of the Iowa State ... CCIM, Senior Associate of Sales at OutcomesMTM, as their Chairperson. ... to the Board and that his peers chose to keep ... provide the best I can for the citizens of Iowa,” ... positioned to provide a special insight to concerns and issues ...
(Date:7/24/2014)... In a recent report by CBS News, the district capital ... criminal penalties associated with possession of small amounts of marijuana. ... Washington DC, giving it one of the most tolerant marijuana ... possession of one ounce of marijuana or less with a ... an ounce of marijuana remain criminal offenses under the new ...
(Date:7/24/2014)... received the Human Papillomavirus Vaccination (HPV) even after ... Pap test results than those who were never ... Sexually Transmitted Diseases . , Researchers from ... of Medicine conducted a cross-sectional study of 235 ... cytology testing. HPV status and demographic and behavioral ...
Breaking Medicine News(10 mins):Health News:TGen-led study seeks to understand why some HIV-positive men are more infectious 2Health News:Memantine Discussed in New Comprehensive Patent Search Report by Ark Patent Intelligence Published at MarketPublishers.com 2Health News:Memantine Discussed in New Comprehensive Patent Search Report by Ark Patent Intelligence Published at MarketPublishers.com 3Health News:Wolnerman Re-elected as Chairperson of Iowa State Board of Health 2Health News:Washington D.C. Decriminalizes Marijuana 2
... Pilot animal study shows promising results in the treatment of ... ... (Vocus) September 9, 2008 -- A pilot animal ... Boston] provides preliminary evidence that delivering neural stem cells (NSC) ...
... WEXFORD, Penn., Sept. 9 Millennium Pharmacy Systems,Inc., ... enabled pharmacy,solutions to senior healthcare facilities, announced today ... Mr. Scardina has served on,the Millennium Board of ... as an independent consultant after serving as an ...
... TARRYTOWN, N.Y., Sept. 9 Focus 28, Inc. ... its new next generation line of,meal replacements and ... of bariatric patients. According to the company,Bariatric RX ... food,supplements also utilize Double A Technology (AAT), a ...
... Mark Jones and William Reed with colleagues at the ... use of Tasers related to ethnicity, gender, race and ... the Use of Conducted Energy Devices by the Houston ... "Conducted Energy Device Program Performance Audit," released by the ...
... 9 Governor Edward G.,Rendell today announced the ... as Secretary of the Pennsylvania Department of Health ... passionate voice for protecting and improving,the health of ... as an effective leader, addressing a variety of,issues ...
... for the Retirement ... month, NORTH CONWAY, N.H., Sept. 9 It,s no ... aging population grows, so,does the need to house them. According ... nursing homes, 39,500 assisted living,facilities and 1,900 continuing care retirement ...
Cached Medicine News:Health News:Neural Stem Cells May Help Repair Spina Bifida in Utero 2Health News:Neural Stem Cells May Help Repair Spina Bifida in Utero 3Health News:Neural Stem Cells May Help Repair Spina Bifida in Utero 4Health News:Focus 28 Begins Shipping Next Generation Line of Meal Replacements and Food Supplements for Bariatric Patients 2Health News:Rice political scientists co-author report on ethnic/racial aspects of Taser use by Houston police 2Health News:Governor Rendell Announces Resignation of Health Secretary Dr. Calvin Johnson 2Health News:SeniorHousingJobs.com Celebrates Its 5th Anniversary 2
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
Medicine Products: